1. Home
  2. CDW vs RPRX Comparison

CDW vs RPRX Comparison

Compare CDW & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CDW Corporation

CDW

CDW Corporation

HOLD

Current Price

$139.81

Market Cap

18.9B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$39.28

Market Cap

16.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDW
RPRX
Founded
1984
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9B
16.4B
IPO Year
1993
2020

Fundamental Metrics

Financial Performance
Metric
CDW
RPRX
Price
$139.81
$39.28
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$185.13
$45.75
AVG Volume (30 Days)
1.9M
3.7M
Earning Date
02-04-2026
02-10-2026
Dividend Yield
1.80%
2.24%
EPS Growth
N/A
N/A
EPS
7.91
1.75
Revenue
$22,099,100,000.00
$2,349,844,000.00
Revenue This Year
$6.77
$37.66
Revenue Next Year
$2.85
$2.34
P/E Ratio
$17.66
$22.39
Revenue Growth
6.09
3.70
52 Week Low
$135.63
$25.16
52 Week High
$222.92
$41.24

Technical Indicators

Market Signals
Indicator
CDW
RPRX
Relative Strength Index (RSI) 40.37 55.11
Support Level $138.37 $38.20
Resistance Level $146.15 $39.50
Average True Range (ATR) 3.47 0.68
MACD -0.51 0.02
Stochastic Oscillator 16.91 72.31

Price Performance

Historical Comparison
CDW
RPRX

About CDW CDW Corporation

CDW Corp is a multi-brand provider of information technology ("IT") solutions to small, medium, and large business, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's broad array of offerings ranges from discrete hardware and software products to integrated IT solutions and services that include on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. The company has five operating segments namely, Corporate, Small Business, Public, CDW UK, and CDW Canada. The Corporate segment generates the majority of its revenue and serves USA private sector business customers.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: